Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
about
Current and emerging azole antifungal agentsFood interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteersEffect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjectsAspergillus fumigatus and aspergillosisA novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.Itraconazole in cyclodextrin solution.Pharmacokinetics of orally administered antifungals in onychomycosis.The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach.Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid.Voriconazole: a new triazole antifungal.Effectiveness of itraconazole on clinical symptoms and radiologic findings in patients with recurrent chronic rhinosinusitis and nasal polyposisIntravenous itraconazole.Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodologyAntifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomesTumor necrosis factor alpha has a protective role in a murine model of systemic candidiasisUpdate on terbinafine with a focus on dermatophytosesReview of antifungal therapy and the severity index for assessing onychomycosis: part I.Role of itraconazole in haematology/oncology.Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs.Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.Antifungal therapy: from amphotericin B to present.Infections in solid-organ transplant recipientsFungal skin infections.Investigation of microemulsion system for transdermal delivery of itraconazoleCurrent perspectives on ophthalmic mycosesCYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safetyItraconazole (Sporanox) in superficial and systemic fungal infections.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Current use of anti-infectives in dermatology.A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies.Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.Clinical pharmacology of antifungal agents in pediatric patients.A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole.Antifungals to treat Candida albicans.
P2860
Q24550733-D69DAC44-48D0-43FD-AECC-4BF3DAA472C5Q24681178-665921C7-47B0-496B-A2E4-5D0712A659ACQ28367515-F57192A6-88BD-4644-A257-9FBA56A847B7Q29617908-BB298FB9-2793-4064-933D-E71BB16317BEQ33573446-1E878246-50B9-4799-AED7-4330881FEE0BQ33637258-35D2B9DD-0786-40D4-A22E-FCE543061040Q33749022-A0D9FB5F-BAC0-4BE7-B4BE-DAEAA05B4805Q33749026-76D99078-AC2D-4CEF-888A-5459416A2F34Q33758961-DA0DFC6C-071D-4DFC-BE15-A645D83E14CAQ33917339-B1067106-D7ED-4075-A2E8-DFBD1D9DC813Q34169948-30516E9B-9400-4EA3-99E7-EFAFE59E0C57Q34284268-4EEE4E32-99E5-4B7D-93B1-08E982C8ADCDQ34291656-5283C896-C052-4FC3-B423-0C935BCE6699Q34293817-F98D5247-E5E4-4373-BD58-251048DBF330Q34335230-E45F8814-3EBE-4528-A212-980FD0439667Q34359090-AFCFF5E3-C4EB-427E-9DDA-AAEBB9B0D82CQ34529190-8090859E-27A7-4682-BD4D-C35DEFDDCDBAQ34620230-E29E76C0-33C6-44A4-B2FD-B4B3BF5D60F6Q34779001-8856C259-1153-4E51-B2A6-6AA3FF72F6F2Q35070963-BA2E5C9B-2F05-466F-B367-798FE5608D60Q35126588-CC364C43-BCCC-40C5-9069-346EDAC94FBFQ35134300-4271A9D9-06DD-4E0A-871D-990601236D98Q35139428-CC9FDC4C-7A17-403E-8F30-5BA0A413DC41Q35245371-450828C5-4EB9-47EB-8A65-B35E8EA4459CQ35376486-4B8FCD07-DC44-48C3-B220-E6E687D8FB76Q35448106-3EC61D08-BE8D-4CB8-94EB-328AB7393C6BQ35554483-C7318E9A-5155-42E9-9259-13B6E8753AE6Q35558829-7B0735C3-C33A-4E01-AFA0-6AB3C37C0527Q35718619-36D1703F-23CE-46CE-B2CF-EFB78CA6C4BCQ35821534-FA55810B-AB7B-418E-9289-2FB44C6F4FECQ35825582-EBC277BB-BA61-4F7C-86C3-E5CAFB5869A4Q35917270-59B4B115-5503-47C2-8E4D-8526A73A4CD8Q35960882-8D24641A-9486-4264-B8F6-49A0EADEAA42Q36233506-D198477B-EFCC-4EE0-8749-06FDB53CB96FQ36388027-047F9973-916C-4500-BA01-006E57819A7CQ36636520-26F8C283-C017-44FC-BD89-F0A6E1062C37Q36905131-7BFA3043-446A-406B-9F28-44E22119D4FBQ36968140-A72B3E01-0D15-4A0E-B8BA-318DDF0A2E38Q37361968-AD6742A7-11D2-44A7-A52B-0802B3ABCA3DQ37763928-24A819AA-AA44-4EC3-A180-FCEA351EE81E
P2860
Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Itraconazole. A review of its ...... erficial and systemic mycoses.
@en
type
label
Itraconazole. A review of its ...... erficial and systemic mycoses.
@en
prefLabel
Itraconazole. A review of its ...... erficial and systemic mycoses.
@en
P1433
P1476
Itraconazole. A review of its ...... erficial and systemic mycoses.
@en
P2093
P304
P356
10.2165/00003495-198937030-00003
P577
1989-03-01T00:00:00Z
P6179
1028189523